MedTrace Logo

Single Dose Adductor Canal Block vs SPANK Block for TKA

NCT03502889 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2019-04-16

No results posted yet for this study

Summary

This is a prospective, randomized control trial to compare SPANK block combined with adductor canal block to adductor canal block alone in treatment of post-operative pain after total knee arthroplasty. The primary outcome is pain control, which will be measured throughout the post-operative course using morphine equivalents of opioid analgesics used during the first 24 hours after surgery. Secondary outcomes include pain scores recorded at 4, 8, 12, 16, 20, and 24 hours post-operatively, cumulative pain score, incidence of post-operative nausea and vomiting, and extent of motor blockade. The study will aid in answering the question of whether SPANK block is an effective adjunct in preventing pain and decreasing opioid requirement after TKA.

Conditions

  • Osteo Arthritis Knee
  • Pain, Postoperative
  • Pain, Acute

Interventions

PROCEDURE

SPANK Block (Sensory Posterior Articular Nerves of the Knee)

Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.

PROCEDURE

Adductor Canal Block

Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee

DRUG

Ropivacaine Hcl 0.5% Inj Vil 30Ml

Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.

DEVICE

Pajunk sonoplex stim needle

Echogenic needle used for ultrasound guided nerve blockade.

Sponsors & Collaborators

  • San Antonio Uniformed Services Health Education Consortium

    lead FED

Principal Investigators

  • Angela M Curell, MD · San Antonio Uniformed Services Health Education Consortium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2020-04-30
Completion
2020-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03502889 on ClinicalTrials.gov